(KYMR) Kymera Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US5015751044

KYMR: IRAK4, STAT6, TYK2, Inflammation, Autoimmune, Small Molecule, PROTAC

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering the discovery and development of small molecule therapeutics designed to selectively degrade disease-causing proteins. By leveraging the bodys inherent protein degradation system, Kymeras approach offers a novel and precise method to target specific proteins implicated in various diseases. The companys lead IRAK4 program is currently in Phase II clinical trials, focusing on treating immunology-inflammation diseases such as hidradenitis suppurativa and atopic dermatitis. Additionally, Kymera is advancing STAT6 for type 2 inflammation in allergic and atopic diseases and TYK2 to address autoimmune and inflammatory conditions. Founded in 2015, Kymera is headquartered in Watertown, Massachusetts, and is at the forefront of innovative drug development targeting protein degradation pathways.

Over the next three months, Kymera Therapeutics stock is expected to show short-term bullish momentum, supported by its recent price movement above the 20-day Simple Moving Average (SMA) of 27.13. However, the stock may face resistance near the 50-day SMA of 30.50 and the 200-day SMA of 40.81, indicating potential challenges in sustaining long-term upward movement. The Average True Range (ATR) of 2.21 suggests manageable volatility. Fundamentally, Kymeras market cap of $2.2 billion reflects investor confidence in its pipeline, despite a negative return on equity (RoE) of -26.79%, typical for a clinical-stage biotech company. The price-to-book (P/B) ratio of 2.61 and price-to-sales (P/S) ratio of 46.48 highlight the markets expectation of future growth, driven by its innovative approach and strategic focus on high-value therapeutic targets.

Additional Sources for KYMR Stock

KYMR Stock Overview

Market Cap in USD 2,297m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Biotechnology
IPO / Inception 2020-08-21

KYMR Stock Ratings

Growth Rating -19.3
Fundamental -
Dividend Rating 0.0
Rel. Strength -9.42
Analysts 4.53/5
Fair Price Momentum 24.63 USD
Fair Price DCF -

KYMR Dividends

No Dividends Paid

KYMR Growth Ratios

Growth Correlation 3m -52.3%
Growth Correlation 12m -29%
Growth Correlation 5y -31.2%
CAGR 5y -2.11%
CAGR/Max DD 5y -0.02
Sharpe Ratio 12m 0.24
Alpha -38.19
Beta 2.092
Volatility 94.92%
Current Volume 535.9k
Average Volume 20d 652.8k
What is the price of KYMR stocks?
As of May 11, 2025, the stock is trading at USD 30.07 with a total of 535,923 shares traded.
Over the past week, the price has changed by -14.77%, over one month by +25.55%, over three months by -16.56% and over the past year by -22.12%.
Is Kymera Therapeutics a good stock to buy?
Neither. Based on ValueRay Analyses, Kymera Therapeutics is currently (May 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of -19.26 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of KYMR as of May 2025 is 24.63. This means that KYMR is currently overvalued and has a potential downside of -18.09%.
Is KYMR a buy, sell or hold?
Kymera Therapeutics has received a consensus analysts rating of 4.53. Therefor, it is recommend to buy KYMR.
  • Strong Buy: 13
  • Buy: 3
  • Hold: 3
  • Sell: 0
  • Strong Sell: 0
What are the forecast for KYMR stock price target?
According to ValueRays Forecast Model, KYMR Kymera Therapeutics will be worth about 29.5 in May 2026. The stock is currently trading at 30.07. This means that the stock has a potential downside of -1.76%.
Issuer Forecast Upside
Wallstreet Target Price 57.7 91.8%
Analysts Target Price 57.7 91.8%
ValueRay Target Price 29.5 -1.8%